GlassScriptPhysician profile
David I Levenson
NPI 1194808063
$3,822.91
in general payments reported to CMS, 2019-2025
39 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $379 · 2021: $396 · 2022: $605 · 2023: $314 · 2024: $763 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041 · Education: $24.04 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.61 |
| Education | $24.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $852.20 | 2019-2025 | |
| Corcept Therapeutics | $345.74 | 2021-2025 | Korlym |
| Amgen INC. | $260.05 | 2019-2025 | Evenity, Prolia, Tepezza |
| Medicure Pharma INC. | $208.87 | 2024-2025 | Zypitamag |
| Horizon Therapeutics Plc | $185.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.36 | 2022-2025 | |
| Mannkind Corporation | $174.69 | 2021-2025 | Afrezza |
| Dexcom, INC. | $171.41 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $166.94 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $141.30 | 2024 | |
| Genzyme Corporation | $125.00 | 2025 | |
| Recordati_rare_diseases_inc. | $97.21 | 2021-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $87.59 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $83.77 | 2020-2024 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $58.02 | 2024 | Crysvita |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.